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OPIOID-KETAMINE AND NORKETAMINE 
CODRUG COMBINATIONS FOR PAIN 
MANAGEMENT 
This application claims priority from US. Provisional 
Patent Application No. 61/072,090, ?led Mar. 27, 2008, the 
disclosure of which is hereby incorporated by reference in its 
entirety. 
FIELD OF THE INVENTION 
The present invention relates to the ?eld of pain manage 
ment, and more particularly to synergistic codrugs compris 
ing an opioid and ketamine or norketamine which have been 
combined to form a single chemical codrug entity. When the 
codrug is administered it produces a synergistic analgesic 
response to pain. 
BACKGROUND OF INVENTION 
Opioids are any endogenous or exogenous compounds that 
bind to an opioid receptor. Opioid receptors are localized 
primarily in the brain, spinal cord, and gastrointestinal tract. 
There are four broad groups of opioids: endogenous opioid 
peptides produced in the body; naturally occurring opioid 
alkaloids such as morphine and codeine; semisynthetic opio 
ids such as hydrocodone and oxycodone, and synthetic opio 
ids such as fentanyl and methadone. When opioids bind to 
their receptors in the brain and spinal cord they block pain 
transmission signals from the periphery of the body. Although 
opioids are very effective for moderate to severe pain, there 
are many well known problems associated with opioid 
therapy. Those problems include serious side effects such as 
cognitive dysfunction, respiratory depression, nausea/vomit 
ing, urinary retention, and constipation. Further, chronic 
opioid therapy often results in the development of tolerance to 
the analgesic effect (resulting in dose escalation) as well as 
physical and psychological dependence. 
N-methyl-D-aspartate antagonists are known to be effec 
tive in suppressing the symptoms of opiate withdrawal. The 
anesthetic ketamine is the most potent N-methyl-D-aspartate 
antagonist available in clinical practice. See, for example, 
WO/2004/045601. 
There is a great need for analgesic medications able to 
provide high e?icacy pain relief while providing more favor 
able pharmacokinetics and reducing the possibility of unde 
sirable effects. Therefore, there is a need for a way to admin 
ister opioids and norketamine to provide a more favorable and 
pharmacokinetic pro?le. 
SUMMARY OF THE INVENTION 
In one embodiment, the present invention provides a 
codrug of the following formula: 
As well as compositions comprising same. The linker may 
be 
Ketamine or 
Norketamine 
wherein Y is O or S; and Rl-O is an opioid moiety and 
R2-NiR3 is a norketamine (R3:H) or ketamine (R3:CH3) 
moiety; or 
m 
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wherein X is nothing, O, S, NH, NR4 (R4:alkyl), (CH2),C 
(where x:l-20, and the alkane moiety can be linear or 
branched), and wherein R2-NiR3 is a norketamine moiety 
(R3:H) or a ketamine moiety (R3:CH3), and Rl-O is an 
opioid moiety. 
In another embodiment, the present invention provides a 
method of synthesis of a codrug comprising a linker, an 
opioid and a ketamine or a norketamine, said method com 
prising: a) covalently bonding a ?rst attachment point of the 
linker to the opioid; b) covalently bonding a second attach 
ment point of the linker to the ketamine or norketamine; and 
c) recovering the codrug, wherein the norketamine is selected 
from the group consisting of S-norketamine, R-norketamine, 
and racemic norketamine; and wherein the ketamine is 
selected from the group consisting of S-ketamine, R-ket 
amine, and racemic ketamine. 
In a further embodiment, the present invention provides a 
method of treatment comprising joining an opioid together 
with a ketamine or a norketamine using a linker to form a 
cleavable codrug; and administering an analgesically effec 
tive amount of the codrug to a human patient, wherein the 
norketamine is selected from the group consisting of S-nor 
ketamine, R-norketamine, and racemic norketamine and 
wherein the ketamine is selected from the group consisting of 
R-ketamine, S-ketamine and racemic ketamine. 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIG. 1 is a graph illustrating the effect of S-norketamine 
and morphine (MOR) combinations, using the tail ?ick test, 
via intraperitoneal administration. FIG. 1A shows tail ?ick 
latencies, and FIG. 1B shows the maximum possible effect. 
FIG. 2 is a graph illustrating the effect of S-norketamine 
and morphine (MOR) via the tail ?ick test, using intrathecal 
administration. FIG. 2A shows tail ?ick latencies, and FIG. 
2B shows the maximum possible effect. 
FIG. 3 is a graph illustrating the effect of morphine (MOR) 
with S-Norketamine (S-NK) using chronic constriction nerve 
injury assay and intraperitoneal administration. FIG. 3A 
shows the measure of paw withdrawal threshold. FIG. 3B 
shows the maximum possible effect. 
FIG. 4 is a graph illustrating the effect of morphine (MOR) 
with S-Norketamine (S-NK) using chronic constriction nerve 
injury assay and intraperitoneal administration. FIG. 4A 
shows the measure of vocalization threshold. FIG. 4B shows 
the maximum possible effect. 
FIG. 5 shows H-NMR analysis of the para-nitrophenoxy 
carbamate of norketamine. 
FIG. 6 shows C-NMR analysis of para-nitrophenoxycar 
bamate of norketamine. 
FIG. 7 shows ESI-MS analysis of a codeine racemic-nor 
ketamine codrug. 
DETAILED DESCRIPTION 
Embodiments of the present invention include novel syn 
ergistic opioid-ketamine and norketamine codrug combina 
tions. Additional embodiments include methods of treating 
and preventing pain in a subject, comprising administration 
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of a codrug combination of the present invention, as well as 
methods of synthesizing the codrugs. 
In accordance with this detailed description, the following 
abbreviations and de?nitions apply. It must be noted that as 
used herein, the singular forms “a”, “an”, and “the” include 
plural referents unless the context clearly dictates otherwise. 
Thus, for example, reference to “compounds” includes a plu 
rality of such compounds and reference to “the dosage” 
includes reference to one or more dosages and equivalents 
thereof known to those skilled in the art, and so forth. 
The publications discussed herein are provided solely for 
their disclosure prior to the ?ling date of the present applica 
tion. Nothing herein is to be construed as an admission that 
the present invention is not entitled to antedate such publica 
tion by virtue of prior invention. Further, the dates of publi 
cation provided may be different from the actual publication 
dates, which may need to be independently con?rmed. 
Unless otherwise stated, the following terms used in the 
speci?cation and claims have the meanings given below: 
By “opioid” is meant any agent that binds to opioid recep 
tors, found principally in the central nervous system and 
gastrointestinal tract. There are four broad classes of opioids: 
endogenous opioid peptides, produced in the body; opium 
alkaloids, such as morphine (the prototypical opioid) and 
codeine; semi-synthetic opioids such as heroin and oxyc 
odone; and fully synthetic opioids such as pethidine and 
methadone that have structures unrelated to the opium alka 
loids. 
“Pharmaceutically acceptable carrier” means a carrier that 
is useful in preparing a pharmaceutical composition that is 
generally safe, non-toxic and neither biologically nor other 
wise undesirable, and includes a carrier that is acceptable for 
human pharmaceutical use as well as veterinary use. “A phar 
maceutically acceptable carrier” as used in the speci?cation 
and claims includes both one and more than one such carrier. 
As used herein, a “mammal” or “individual” refers to 
humans or animals such as dogs, cats, horses and the like and 
farm animals such as cows, pigs, guinea pigs and the like. 
“Treating” or “treatment” of a disease and/orpain includes: 
(1) preventing the disease/pain, i.e., causing the clinical 
symptoms of the disease not to develop in a mammal 
(preferable a human) that may be exposed to or predis 
posed to the disease but does not yet experience or 
display symptoms of the disease, 
(2) inhibiting the disease/pain, i.e., arresting or reducing 
the development of the disease or its clinical symptoms, 
or 
(3) relieving the disease/pain, i.e., causing regression of the 
disease or its clinical symptoms. 
A “therapeutically effective amount” means the amount of 
a compound that, when administered to a mammal for treat 
ing a disease, is suf?cient to effect such treatment for the 
disease. The “therapeutically effective amount” will vary 
depending on the compound, the disease and its severity and 
the age, weight, etc., of the mammal to be treated. 
“Pharmaceutically acceptable salt” refers to pharmaceuti 
cally acceptable salts of norketamine which salts are derived 
from a variety of organic and inorganic counter ions well 
known in the art and include, by way of example only, 
sodium, potassium, calcium, magnesium, ammonium, tet 
raalkylammonium, and the like; and when the molecule con 
tains a basic functionality, salts of organic or inorganic acids, 
such as hydrochloride, hydrobromide, tartrate, fumarate, 
mesylate, acetate, maleate, oxalate and the like. 
“Optional” or “optionally” means that the subsequently 
described event or circumstance may, but need not, occur, and 
that the description includes instances where the event or 
circumstance occurs and instances in which it does not. 
The term “subject in need thereof” refers to any animal in 
need of relief from pain, or the same or similar symptoms 
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caused by any other disease or condition. Preferably, the 
subject is a mammal. More preferably, the subject is human. 
“Synergistic effect” and “supra-additive effect” refer to 
action of two agents such as drugs or chemicals producing an 
effect, in this case, analgesia, which is greater than the simple 
addition of the effects of each drug administered by them 
selves. 
“Mammal” or “individual” refers to humans or animals 
such as dogs, cats, horses, and the like, and farm animals, such 
as cows, pigs, guinea pigs and the like. 
As used herein, (including the claims), the term alkylene or 
alkylene group is to be understood in the broadest sense to 
mean hydrocarbon residues which can be linear, i.e., straight 
chain, or branched, and can be acyclic or cyclic residues or 
comprise any combination of acyclic and cyclic subunits. 
Further, the term alkylene as used herein expressly includes 
saturated groups as well as unsaturated groups which latter 
groups contain one or more, for example, one, two, or three, 
double bonds and/ or triple bonds. The term alkylene includes 
substituted and unsubstituted alkylene groups; one or more 
carbons may be replaced with heteroatoms O or S; and the 
alkylene may be pegylated. In accordance with the above 
substitutions, the alkylene is also understood to include all 
isomers, diastereiomers, enantiomers; and cis and trans geo 
metrical isomers. 
Examples of alkylene residues containing from 1 to 20 
carbon atoms are methylene, ethylene, propylene, butylene, 
pentylene, hexylene, heptylene, octylene, nonylene, 
decylene, undecylene, dodecylene, tetradecylene, hexade 
cylene, octadecylene, and eicosylene, the n-isomers of all 
these residues, isopropylene, isobutylene, l-methylbutylene, 
isopentylene, neopentylene, 2,2-dimethylbutylene, 2-meth 
ylpentylene, 3-methylpentylene, isohexylene, 2,3,4-trimeth 
ylhexylene, isodecylene, sec-butylene, tertbutylene, or tert 
pentylene. In certain preferred embodiments, the alkylene 
contains from 1 to 4 carbons. 
Unsaturated alkylene residues are, for example, alkenylene 
residues such as vinylene, l-propenylene, 2-propenylene 
(:allyl), 2-butenylene, 3-butenylene, 2-methyl-2-butenylene, 
3-methyl-2-butenylene, 5-hexenylene, or 1,3-pentadi 
enylene, or alkynylene residues such as ethynylene, l-propy 
nylene, 2-propynylene (:propargyl), or 2-butynylene. Alky 
lene residues can also be unsaturated when they are 
substituted. 
Unless stated otherwise, the term alkylene preferably com 
prises acyclic saturated hydrocarbon residues containing 
from 1 to 6 carbon atoms which can be linear or branched. 
Additionally, included are acyclic unsaturated hydrocarbon 
residues containing from 2 to 6 carbon atoms which can be 
linear or branched like (C.sub.2-C.sub.6)-alkenylene and 
(C.sub.2-C.sub.6)-alkynylene, and cyclic alkylene groups 
containing from 3 to 8 ring carbon atoms, in particular from 3 
to 6 ring carbon atoms. A particular group of saturated acyclic 
alkylene residues is formed by (C.sub.l-C.sub.4)-alkylene 
residues like methylene, ethylene, n-propylene, isopropy 
lene, n-butylene, isobutylene, sec-butylene, and tert-buty 
lene. 
The present invention provides codrugs, compositions and 
synthetic methods wherein an opioid analgesic and ketamine 
or norketamine, or one of its enantiomers, are combined to 
produce a single chemical codrug entity. It is administered in 
amounts to produce a synergistic (greater than additive) anal 
gesic response to pain. The pain may be acute, chronic, or 
cancer related. The codrugs of the present invention have a 
slower rate of development of opioid tolerance and depen 
dence, with diminished clinical side effects than those seen 
with opioid-only therapies for pain. 
Typical side effects known to occur following the admin 
istration of an N-methyl-D-asparate antagonist, such as nor 
ketamine, are diminished when the codrug is used; however, 
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the analgesic activity is retained. The spectrum of treatable 
pain symptoms include nociceptive pain, such as low back 
pain and postsurgical pain, and neuropathic pain, such as 
diabetic neuropathy andAle related neuropathy. These pain 
symptoms are more effectively treated using the codrugs of 
the present invention more effectively than by treatment with 
opioids only. 
The codrug of the present invention comprises two differ 
ent drugs, which when combined have a synergistic analgesic 
effect in the form of a single chemical entity. The two drugs 
are connected directly or by means of a cleavable covalent 
linker, such as an ester, an amide, and a carbamate, which is 
cleaved in vivo to regenerate the individual drug entities at the 
desired site of action. 
Ketamine (2-(2-chlorophenyl)-2-(methylamino)-cyclo 
hexanone) is a general anesthetic used by anesthesiologists, 
veterinarians, and researchers. However, Ketamine is well 
known to have important clinical disadvantages. Particularly, 
ketamine is known to cause disturbing emergence reactions, 
including delirium, dysphoria, and unpleasant dreams (Le 
ung et al., 1985, J. Med. Chem. 29: 2396-2399). Current 
pharmaceutical compositions of ketamine are racemic mix 
tures of S- and R-ketamine, though S-ketamine has been 
found recently to be twice as potent as R-ketamine and to 
allow faster recovery with fewer negative side effects than the 
racemic mixture (C. S. T. Aun, 1999, Br. J. Anaesthesia 83: 
29-41). One of the principal metabolic products of ketamine 
is norketamine (2-(2-chlorophenyl)-2-amino-cyclohex 
anone). Ketamine has also been known also to have analgesic 
properties (Domino et al., 1965, Clin. Pharmacol. Ther. 6: 
279); profound analgesia can be achieved with subanesthetic 
doses of ketamine (Bovill, 1971, Br. J. Anaesth. 43: 496; 
Sadove et al., 1971, Anesth. Analg. 50: 452-457). 
Studies have shown that ketamine is converted metaboli 
cally through demethylation to norketamine, in vivo, at rates 
dependent on the route of administration, with oral and rectal 
administrations having the fastest rates due to a high degree of 
?rst pass metabolism in the liver (see, e.g., Grant et al., 1981, 
Br. J. Anaesth. 53: 805-810; Grant et al., 1981, Br. J. Anaesth. 
55: 1107-1111; Leung et al., 1985, J. Med. Chem. 29: 2396 
2399; Malinovsky et al., 1996, Br. J Anaesthesia 77: 203 
207). Norketamine binds the NMDA receptor less tightly 
than either S- or R-ketamine (Ebert et al., 1997, Eur. J. Pharm. 
333: 99-104) and norketamine is speculated to have an anes 
thetic and analgesic potency one third that of ketamine (C. S. 
T. Aun, 1999, Br. J. Anaesthesia 83: 29-41), perhaps explain 
ing the absence of administration of norketamine as an anal 
gesic in the prior art. 
Initial studies suggest that norketamine produces stereo se 
lective effects on locomotor activity, schedule-controlled 
operant responding, abuse liability and autonomic side 
effects [Dwoskin et al., 1999; Risner et al., 1988; Stairs et al., 
(in press)]. This suggests that it may be possible to separate 
the desirable effect (analgesic) from the undesirable side 
effects of ketamine. 
The structures of R- and S-norketamine are presented 
below: 
R S 
""an NH2 
0 O 
R—norketamine S—norketamine 
The present invention relates to pharmaceutical composi 
tions and synthetic methods wherein an opioid analgesic and 
a ketamine or a norketamine, including S-norketamine, 
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R-norketamine, and racemic norketamine and S-ketamine, 
R-ketamine and racemic ketamine, are combined to produce 
a single chemical co-drug entity and administered in amounts 
to produce a synergistic analgesic response to pain, including 
acute, chronic and/ or cancer-related pain. 
The codrugs of the present invention have a slower rate of 
opioid tolerance development and dependence with dimin 
ished clinical side effects than typically observed with con 
ventional opioid only therapy for pain. Typical side effects 
known to occur following administration of ketamine and 
norketamine are also expected to be diminished. 
Codrugs of the present invention comprise an opioid and a 
ketamine or a norketamine within a single chemical entity. 
The two drugs may be connected directly or by means of a 
cleavable covalent linker (e.g., ester, carbonate, amide, car 
bamate, etc.) which is cleaved in vivo upon administration to 
regenerate the active drug entities. By providing two drugs as 
a single entity, instead of as a physical mixture, the codrugs of 
the present invention provide advantages including improved 
drug stability, improved targeting of drugs to the site of action 
and a more desirable pharmacokinetic properties. This is 
especially true for drugs with differing physiochemical prop 
erties, such as lipid solubility. 
When the opioid and the norketamine are linked together 
and administered as a co-drug, these molecules would 
undergo the same pharmacokinetics prior to cleavage. Spe 
ci?cally, where different molecules have substantially differ 
ent partition coef?cients, absorption across membranes 
would be the same. Other advantages of administering differ 
ent molecules as co-drugs is described in Synthesis and 
Hydrolytic Behavior of Two Novel Tripartate Codrugs of 
Naltrexone and 6B-Naltrexone with Hydroxybupropion as 
Potential Alcohol Abuse and Smoking Cessation Agents, 
Hamad et al., Bioorganic and Medicinal Chemistry, 2006, 
volume 14, pages 7051-7061; the disclosure of which is 
hereby incorporated by reference in its entirety. 
The present invention provides a codrug of the following 
formula: 
Ketamine or 
Norketamine m 
wherein the linker is selected from the group consisting of 
the following formulas: 
wherein Y is O or S; and Rl-O is an opioid moiety and 
R2-NiR3 is a norketamine (R3:H) or ketamine (R3ICH3) 
moiety 
wherein X is a bond, 0, S, NH, NR4 (R4:alkyl), (CH2),C 
(where x:1-20, and the alkane moiety can be linear or 
branched), and wherein R2-NiR3 is a norketamine moiety 
(R3:H) or a ketamine moiety (R3ICH3), and Rl-O is an 
opioid moiety. 
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One embodiment of the present invention is a composition 
of the following formula: 
la 
OR 
o 
N 
. O H H \CH3 
0‘“ 
NH X o‘ 
o o 
and compositions thereof, and compositions thereof, 
wherein X is a bond, O, S, NH, NR1 (RlIalkyl), (CH2),C 
(XII-20, and the alkane moiety can be linear or branched), 
R:H, CH3, RiCOi (where RIalkyl), and where * indi 
cates the racemic, S- or R-form of the norketamine moiety. 
Another embodiment of the present invention is a compo 
sition of the following formula: 
1b 
OR 
o 
N 
. O H H \CH3 
HN 0“,“ 
Cl T 
Y 
and compositions thereof, wherein Y:O, S, and R:H, 
CH3, RCOi (where RIalkyl) and * indicates racemic, S- or 
R-form of norketamine. 
The compound of formula II is a S-norketamine:morphine 
codrug. 
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OH 
H H 
\\ \\ \\ 
CH3 O 
HN\"/O 
O 
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The compound of formula III is a R-norketamine:mor 
phine codrug 
Codrugs of the present invention may include a codrug 
comprising codeine linked with racemic norketamine as 
shown: 
Cl 
Codrugs of the present invention may also include a codrug 
comprising codeine linked with racemic ketamine as shown: 
Cl 
Other codrugs may include, but are not limited to, a codrug 
wherein S-ketamine is linked to morphine by a carbamate 
linker; a codrug wherein S-ketamine is linked to codeine by a 
carbamate linker; a codrug wherein S-ketamine is linked to 
oxycodone by a carbamate linker; a codrug wherein S-ket 
amine is linked to 3-acetylmorphine by a carbamate linker; a 
codrug wherein S-ketamine is linked to oxymorphone by a 
carbamate linker; a codrug wherein S-ketamine is linked to 
hydromorphone by a carbamate linker; a codrug wherein 
S-ketamine is linked to butorphenol by a carbamate linker; a 
codrug wherein S-ketamine is linked to bupernorphine by a 
carbamate linker; a codrug wherein S-ketamine is linked to 
US 8,710,070 B2 
tramadol by a carbamate linker; and a codrug wherein S-ket 
amine is linked to levorphanol by a carbamate linker. 
Other codrugs may include, but are not limited to, a codrug 
wherein S-norketamine is linked to morphine by a carbamate 
linker; a codrug wherein S-norketamine is linked to codeine 
by a carbamate linker; a codrug wherein S-norketamine is 
linked to oxycodone by a carbamate linker; a codrug wherein 
S-norketamine is linked to 3-acetylmorphine by a carbamate 
linker; a codrug wherein S-norketamine is linked to oxymor 
phone by a carbamate linker; a codrug wherein S-norket 
amine is linked to hydromorphone by a carbamate linker; a 
codrug wherein S-norketamine is linked to butorphenol by a 
carbamate linker; a codrug wherein S-norketamine is linked 
to bupernorphine by a carbamate linker; a codrug wherein 
S-norketamine is linked to tramadol by a carbamate linker; 
and a codrug wherein S-norketamine is linked to levorphanol 
by a carbamate linker. 
Examples of opioids for combination with norketamine 
include all therapeutically useful and pharrnacologically 
active opioids and opioid metabolites and their respective 
pure enantiomers and/or diastereiomers. Representative 
examples include but are not limited to dihydroetorphine, 
butorphanol, pentazocine, morphine, phenazocine, hydro 
morphone, codeine, 3-acetylmorphine, oxymorphone, 
methadone, propoxyphene, oxycodone, tramadol, hydroc 
odone, buprenorphine, levorphanol, dihydrocodeine, 
L-acetylmethadol, ethylmorphine, nalbuphine, etorphine, 
buprenorphine, normethadone, dihydromorphine, noroxyc 
odone, normorphine, norlevorphanol. 
In certain embodiments, the general multi-step synthetic 
procedure for preparation of the codrug includes: reacting 
para-nitrophenyl chloroformate with an opiate drug contain 
ing a hydroxy group in the presence of triethyl amine and dry 
chloroform and the solution is cooled to 0 degrees C. The 
resulting 6-O-para-nitrophenoxycarbonate ester of an opiate 
drug is then reacted with a norketamine to yield the ketamine 
opioid or norketamine-opioid codrug. 
Generally speaking the opioids and ketamine or norket 
amine of the present invention that are synthesized into co 
drugs in accordance with the present invention will contain a 
free hydroxyl group or another equivalent moiety capable of 
being acylated. Examples of other moieties include primary 
or secondary amines, or carbonyl containing moieties. 
Example of opioids suitable for synthesis of the codrugs in 
accordance with the present invention include dihydroetor 
phine, butorphanol, pentazocine, morphine, 3-acetylmor 
phine, phenazocine, hydromorphone, codeine, oxymor 
phone, methadone, propoxyphene, oxycodone, tramadol, 
hydrocodone, buprenorphine, levorphanol, dihydrocodeine, 
L-acetylmethadol, ethylmorphine, nalbuphine, etorphine, 
buprenorphine, normethadone, dihydromorphine, noroxyc 
odone, normorphine, norlevorphanol, as well as any pharma 
ceutically acceptable salts, metabolites, enantiomers and 
diastereiomers thereof. 
S-norketamine, R-norketamine, and racemic norketamine, 
as well as S-ketamine, R-ketamine, and racemic ketamine, 
are suitable for use in the present invention. 
Compositions of the present invention can be synthesized 
using the methods readily available to the skilled artisan, 
including those methods known in the art of synthetic organic 
chemistry, or variations thereon as readily appreciated and 
readily performable by those skilled in the art. Moreover, the 
synthesis methods known in the art are not intended to com 
prise a comprehensive list of all means by which the compo 
sitions described and claimed in this patent application may 
be synthesized. Some of the compounds of the invention may 
have stereogenic centers. The compounds may, therefore, 
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exist in at least two and often more stereoisomeric forms. The 
present invention encompasses all stereoisomers of the com 
pounds whether free from other stereoisomers or admixed 
with other stereoisomers in any proportion and thus includes, 
for instance, racemic mixture of enantiomers as well as the 
diasteriomeric mixture of isomers. Thus, when using the term 
“compound”, it is understood that all stereoisomers are 
included. 
The compounds of the present invention may be obtained 
or used as inorganic or organic salts using methods known to 
those skilled in the art. It is well known to one skilled in the art 
that an appropriate salt form is chosen based on physical and 
chemical stability, ?owability, hydroscopicity and solubility. 
Pharmaceutically acceptable salts of the present invention 
with an acidic moiety may be optionally formed from organic 
and inorganic bases. For example with alkali metals or alka 
line earth metals such as sodium, potassium, lithium, cal 
cium, or magnesium or organic bases and N-tetraalkylammo 
nium salts such as N-tetrabutylammonium salts. Similarly, 
when a compound of this invention contains a basic moiety, 
salts may be optionally formed from organic and inorganic 
acids. 
For example salts may be formed from acetic, propionic, 
lactic, citric, tartaric, succinic, fumaric, maleic, malonic, 
mandelic, malic, phthalic, hydrochloric, hydrobromic, phos 
phoric, nitric, sulfuric, methanesulfonic, naphthalene 
sulfonic, benzenesulfonic, toluenesulfonic, camphorsul 
fonic, and similarly known acceptable acids. The compounds 
can also be used in the form of esters, carbamates and other 
conventional prodrug forms, which when administered in 
such form, convert to the active moiety in vivo. When using 
the term “compound” herein, it is understood that all salts are 
included. 
The term “pharmaceutically acceptable salt” as used herein 
is intended to include the non-toxic acid addition salts with 
inorganic or organic acids, e.g. salts with acids such as hydro 
chloric, phosphoric, sulfuric, maleic, acetic, citric, succinic, 
benzoic, fumaric, mandelic, p-toluene-sulfonic, methane 
sulfonic, ascorbic, lactic, gluconic, tri?uoroacetic, 
hydroiodic, hydrobromic, and the like. Examples of pharma 
ceutically acceptable salts include, but are not limited to, 
mineral or organic acid salts of basic residues such as amines; 
alkali or organic salts of acidic residues such as carboxylic 
acids; and the like. 
Pharmaceutically acceptable salts of the compounds of the 
invention can be prepared by reacting the free acid or base 
forms of these compounds with a stoichiometric amount of 
the appropriate base or acid in water or in an organic solvent, 
or in a mixture of the two; generally, nonaqueous media like 
ether, ethyl acetate, ethanol, isopropanol, or acetonitrile are 
preferred. Lists of suitable salts are found in Remington ’s 
Pharmaceutical Sciences, 17th ed., Mack Publishing Com 
pany, Easton, Pa., 1985, p. 1418, the disclosure of which is 
hereby incorporated by reference in its entirety. 
The codrugs and compositions and formulations thereof 
effective compounds may be administered alone or in con 
junction with other pharrnaceutically active compounds. It 
will be understood by those skilled in the art that pharmaceu 
tically active compounds to be used in combination with the 
compounds described herein will be selected in order to avoid 
adverse effects on the recipient or undesirable interactions 
between the compounds. As used herein, the term “active 
ingredient” or “active agent” is meant to include compounds 
described herein when used alone or in combination with one 
or more additional pharmaceutically active compounds. The 
amount of the compounds described herein required for use in 
the various treatments of the present invention depend, inter 
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alia, on the route of administration, the age and weight of the 
animal (e.g. human) to be treated and the severity of the 
condition being treated. 
The compositions of the present invention and such second 
therapeutic agent can be administered separately or as a 
physical combination in a single dosage unit, in any dosage 
form and by various routes of administration, as described 
above. The compositions of the present invention may be 
formulated together with the second therapeutic agent in a 
single dosage unit (that is, combined together in one dosage 
form). When the compositions of the present invention and 
the second therapeutic agent are not formulated together in a 
single dosage unit, they may be administered essentially at 
the same time, or in any order; for example, the compositions 
of the present invention may be administered ?rst, followed 
by administration of the second agent. 
Formulations 
It is preferred to administer the codrugs of the present 
invention as pharmaceutical formulations. Useful formula 
tions comprise a codrug and one or more pharmaceutically 
acceptable carriers. The term “pharmaceutically acceptable” 
means compatible with the other ingredients of the formula 
tion and not toxic to the recipient. Pharmaceutical composi 
tions of the invention are suitable for use in a variety of drug 
delivery systems. Suitable formulations for use in the present 
invention are found in Remington ’s Pharmaceutical Sci 
ences, Mace Publishing Company, Philadelphia, Pa., 17th ed. 
(1985). 
In general, the codrugs of the subject invention will be 
administered in a therapeutically effective amount by any of 
the accepted modes of administration for agents that serve 
similar utilities. Such compositions are prepared in a manner 
well known in the pharmaceutical art. In one probable mode 
of administration, the codrug will be administered by the oral 
route. 
The actual amount of the codrug will depend on a number 
of factors, such as the severity of the pain to be treated, the age 
and relative health of the subject, the potency of the agent 
used, the route and form of administration, and other factors. 
Toxicity and therapeutic ef?cacy of such compounds can be 
determined by standard pharmaceutical procedures in vitro or 
in experimental animals, e.g., for determining the LD50 (the 
dose lethal to 50% of the population) and the ED50 (the dose 
therapeutically effective in 50% of the population). The dose 
ratio between toxic and therapeutic effects is the therapeutic 
index and it can be expressed as the ratio LDSO/EDSO. Data 
obtained in vitro and in animal studies can be used in formu 
lating a range of dosage foruse in humans. The dosage of such 
compounds lies preferably within a range of circulating con 
centrations that include the ED50 with little or no toxicity. The 
do sage may vary within this range depending upon the do sage 
form employed and the route of administration utilized. A 
dose may be formulated in animal models to achieve a circu 
lating plasma concentration range which includes the ED50 
(i.e., the dose of the test compound which achieves a half 
maximal inhibition of symptoms). Such information can be 
used to more accurately determine useful doses in humans. 
Levels in plasma may be measured, for example, by high 
performance liquid chromatography. 
In preparing the compositions of this invention, the codrug 
may be mixed with an excipient, diluted by an excipient or 
enclosed within a carrier which can be in the form of a 
capsule, sachet, paper or other container. When the excipient 
serves as a diluent, it can be a solid, semi-solid, or liquid 
material, which acts as a vehicle, carrier or medium for the 
active ingredient. Thus, the compositions can be in the form 
of tablets, pills, powders, lozenges, sachets, cachets, elixirs, 
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suspensions, emulsions, solutions, syrups, aerosols (as a solid 
or in a liquid medium), ointments containing, for example, up 
to 10% by weight of the active compound, soft and hard 
gelatin capsules, suppositories, sterile injectable solutions, 
and sterile packaged powders. 
The quantity of codrug in the pharmaceutical composition 
and unit dosage form thereof may be varied or adjusted 
widely depending upon the particular application, the manner 
or introduction, the potency of the particular compound, and 
the desired concentration. The term “unit dosage forms” 
refers to physically discrete units suitable as unitary dosages 
for human subjects and other mammals, each unit containing 
a predetermined quantity of active material calculated to pro 
duce the desired therapeutic effect, in association with a suit 
able pharmaceutical excipient. 
The codrug is effective over a wide dosage range and is 
generally administered in a pharmaceutically or therapeuti 
cally effective amount. It will be understood, however, that 
the amount of the codrug actually administered will be deter 
mined by a physician, in the light of the relevant circum 
stances, including the condition to be treated, the severity of 
the disease being treated, the chosen route of administration, 
the actual compound administered, the age, weight, and 
response of the individual patient, the severity of the patient’ s 
symptoms, and the like. Typically, the physician will admin 
ister the compound until a dosage is reached that achieves the 
desired effect. 
The codrugs of the invention will be administered in a 
therapeutically effective amount by any of the accepted 
modes of administration. The codrugs can be administered by 
a variety of routes, including, but not limited to, oral, 
parenteral (e.g., subcutaneous, intravenous, intramuscular, 
intraperitoneal, intraarterial), intralesional, neuroaxial (epi 
dural, intrathecal, intracerebral), topical, intranasal, localized 
(e.g., surgical application or surgical suppository), sublin 
gual, submucosal, rectal, vaginal, pulmonary (e.g., aerosols, 
inhalation, or powder) and transdermal routes of administra 
tion. The compounds can be administered continuously by 
infusion or by bolus injection. Such compositions are pre 
pared in a manner well known in the pharmaceutical art. 
The actual amount of the codrug of the subject invention 
will depend on a number of factors, such as the severity of the 
pain and/ or condition, i.e., the condition or disease to be 
treated, the age and relative health of the subject, the potency 
of the compound used, the route and form of administration, 
and other factors. 
The amount of the pharmaceutical composition adminis 
tered to the patient will vary depending upon what is being 
administered, the purpose of the administration, such as pro 
phylaxis or therapy, the state of the patient, the manner of 
administration, and the like. In therapeutic applications, com 
positions are administered to a patient already suffering from 
a disease in an amount suf?cient to cure or at least partially 
arrest the symptoms of the disease and its complications. An 
amount adequate to accomplish this is de?ned as “therapeu 
tically effective dose.” Amounts effective for this use will 
depend on the disease condition being treated as well as by the 
judgment of the attending physician depending upon factors 
such as the severity of the pain, the age, weight and general 
condition of the patient, and the like. 
The compositions administered to a patient are in the form 
of pharmaceutical compositions described supra. These com 
positions may be sterilized by conventional sterilization tech 
niques, or may be sterile ?ltered. When employed as pharma 
ceuticals, the compounds of the subject invention are usually 
administered in the form of pharmaceutical compositions. 
This invention also includes pharmaceutical compositions, 
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which contain as the active ingredient, one or more of the 
compounds of the subject invention above, associated with 
one or more pharmaceutically acceptable carriers or excipi 
ents. The excipient employed is typically one suitable for 
administration to human subjects or other mammals. 
For oral preparations, the agents can be used alone or in 
combination with appropriate additives to make tablets, pow 
ders, granules or capsules, for example, with conventional 
additives, such as lactose, mannitol, corn starch or potato 
starch; with binders, such as crystalline cellulose, cellulose 
derivatives, acacia, corn starch or gelatins; with disintegra 
tors, such as corn starch, potato starch or sodium carboxym 
ethylcellulose; with lubricants, such as talc or magnesium 
stearate; and if desired, with diluents, buffering agents, moist 
ening agents, preservatives and/or ?avoring agents. By way 
of example, for preparing solid compositions such as tablets, 
the principal active ingredient is mixed with a pharmaceutical 
excipient to form a solid preformulation composition con 
taining a homogeneous mixture of a compound of the present 
invention. When referring to these preformulation composi 
tions as homogeneous, it is meant that the active ingredient is 
dispersed evenly throughout the composition so that the com 
position may be readily subdivided into equally effective unit 
dosage forms such as tablets, pills and capsules. The compo 
sitions of the invention can be formulated so as to provide 
rapid, sustained or delayed release of the active ingredient 
after administration to the patient by employing procedures 
known in the art. 
The tablets or pills of the present invention may be coated 
or otherwise compounded to provide a dosage form affording 
the advantage of prolonged action. For example, the tablet or 
pill can comprise an inner dosage and an outer dosage com 
ponent, the latter being in the form of an envelope over the 
former. The two components can be separated by an enteric 
layer, which serves to resist disintegration in the stomach and 
permit the inner component to pass intact into the duodenum 
or to be delayed in release. A variety of materials can be used 
for such enteric layers or coatings, such materials including a 
number of polymeric acids and mixtures of polymeric acids 
with such materials as shellac, alcohol, and cellulose acetate. 
The preferred parenteral form depends on the intended 
mode of administration and therapeutic application. The 
compositions can also include, depending on the formulation 
desired, pharmaceutically-acceptable, non-toxic carriers or 
diluents, which are de?ned as vehicles commonly used to 
formulate pharmaceutical compositions for animal or human 
administration. The diluent is selected so as not to affect the 
biological activity of the combination. Examples of such 
diluents are distilled water, physiological phosphate-buffered 
saline, Ringer’s solutions, dextrose solution, and Hank’s 
solution. In addition, the pharmaceutical composition or for 
mulation may also include other carriers, adjuvants, or non 
toxic, nontherapeutic, nonimmunogenic stabilizers and the 
like. Also included may be carrier molecules such as pro 
teoglycans. Speci?c examples of such carrier molecules 
include, but are not limited to, glycosaminoglycans such as 
heparin sulfate, hyaluronic acid, keratan-sulfate, chondroitin 
4-sulfate, chondroitin 6-sulfate, heparan sulfate and dermatin 
sulfate, perlecan, and pento polysulfate. 
Compositions for inhalation or insu?lation include solu 
tions and suspensions in pharmaceutically acceptable, aque 
ous or organic solvents, or mixtures thereof, and powders. 
The liquid or solid compositions may contain suitable phar 
maceutically acceptable excipients as described supra. The 
compositions may be administered by the oral or nasal respi 
ratory route for local or systemic effect. Compositions in 
preferably pharmaceutically acceptable solvents may be 
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nebulized by use of inert gases. Nebulized solutions may be 
inhaled directly from the nebuliZing device or the nebuliZing 
device may be attached to a face mask tent, or intermittent 
positive pressure breathing machine. Solution, suspension, or 
powder compositions may be administered, preferably orally 
or nasally, from devices which deliver the formulation in an 
appropriate manner. 
The liquid forms in which the novel compositions of the 
present invention may be incorporated for administration 
orally or by injection include aqueous solutions, suitably 
?avored syrups, aqueous or oil suspensions, and ?avored 
emulsions with edible oils such as corn oil, cottonseed oil, 
sesame oil, coconut oil, or peanut oil, as well as elixirs and 
similar pharmaceutical vehicles. 
Another preferred formulation employed in the methods of 
the present invention employs transdermal delivery devices 
(“patches”). Such transdermal patches may be used to pro 
vide continuous or discontinuous infusion of the compounds 
of the present invention in controlled amounts. The construc 
tion and use of transdermal patches for the delivery of phar 
maceutical agents is well known in the art. See, e.g., US. Pat. 
No. 5,023,252, issued Jun. 11, 1991, herein incorporated by 
reference. Such patches may be constructed for continuous, 
pulsatile, or on demand delivery of pharmaceutical agents. 
Direct or indirect placement techniques may be used when 
it is desirable or necessary to introduce the pharmaceutical 
composition to the brain. Direct techniques usually involve 
placement of a drug delivery catheter into the host’s ventricu 
lar system to bypass the blood-brain barrier. One such 
implantable delivery system used for the transport of biologi 
cal factors to speci?c anatomical regions of the body is 
described in US. Pat. No. 5,011,472, which is herein incor 
porated by reference. 
Indirect techniques, which are generally preferred, usually 
involve formulating the compositions to provide for drug 
latentiation by the conversion of hydrophilic drugs into lipid 
soluble drugs. Latentiation is generally achieved through 
blocking of the hydroxy, carbonyl, sulfate, and primary amine 
groups present on the drug to render the drug more lipid 
soluble and amenable to transportation across the blood-brain 
barrier. Alternatively, the delivery of hydrophilic drugs may 
be enhanced by intra-arterial infusion of hypertonic solutions 
which can transiently open the blood-brain barrier. 
The codrugs of this invention may be administered in a 
sustained release form. Suitable examples of sustained-re 
lease preparations include semipermeable matrices of solid 
hydrophobic polymers, which matrices are in the form of 
shaped articles, e.g., ?lms, or microcapsules. Examples of 
sustained-release matrices include polyesters, hydrogels 
(e.g., poly(2-hydroxyethyl-methacrylate) as described by 
Langer et al., J. Biomed. Mater. Res. 15: 167-277 (1981) and 
Langer, Chem. Tech. 12: 98-105 (1982) or poly(vinyl alco 
hol)), polylactides (US. Pat. No. 3,773,919), copolymers of 
L-glutamic acid and gamma ethyl-L-glutamate (Sidman et 
al., Biopolymers 22: 547-556, 1983), non-degradable ethyl 
ene-vinyl acetate (Langer et al., supra), degradable lactic 
acid-glycolic acid copolymers such as the LUPRON 
DEPOTTM (i.e. injectable microspheres composed of lactic 
acid-glycolic acid copolymer and leuprolide acetate), and 
poly-D-(—)-3-hydroxybutyric acid (EP 133,988). The com 
pounds of this invention can be administered in a sustained 
release form, for example a depot injection, implant prepara 
tion, or osmotic pump, which can be formulated in such a 
manner as to permit a sustained release of the active ingredi 
ent. Implants for sustained release formulations are well 
known in the art. Implants may be formulated as, including 
but not limited to, microspheres, slabs, with biodegradable or 
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non-biodegradable polymers. For example, polymers of lac 
tic acid and/or glycolic acid form an erodible polymer that is 
well-tolerated by the host. The implant is placed in proximity 
to the site of protein deposits (e.g., the site of formation of 
amyloid deposits associated with neurodegenerative disor 
ders), so that the local concentration of active agent is 
increased at that site relative to the rest of the body. 
In order to enhance serum half-life, the compounds may be 
encapsulated, introduced into the lumen of liposomes, pre 
pared as a colloid, or other conventional techniques may be 
employed which provide an extended serum half-life of the 
compounds. A variety of methods are available for preparing 
liposomes, as described in, e.g., Szoka et al., US. Pat. Nos. 
4,235,871, 4,501,728 and 4,837,028 each of which is incor 
porated herein by reference. 
The dosage when administered alone or in combination 
with a second therapeutic agent may vary depending upon 
various factors such as the pharmacodynamic characteristics 
of the particular agent and its mode and route of administra 
tion, the age, health and weight of the recipient, the nature and 
extent of the symptoms, the kind of concurrent treatment, the 
frequency of treatment, and the effect desired, as described 
above. The proper dosage of a composition of the present 
invention when administered in combination with the second 
therapeutic agent will be readily ascertainable by a medical 
practitioner skilled in the art, once armed with the present 
disclosure. Upon improvement of a patient’s condition, a 
maintenance dose of a composition of the present invention 
may be administered, if necessary. Subsequently, the dosage 
or frequency of administration, or both, may be reduced, as a 
function of the symptoms, to a level at which the improved 
condition is retained. When the symptoms have been allevi 
ated to the desired level, treatment should cease. Patients may, 
however, require intermittent treatment on a long-term basis 
upon any recurrence of pain. 
The compounds recited herein are presented for exemplary 
purposes only, and should not be construed as being a limited 
presentation of compounds of the present invention. 
It will be apparent to those skilled in the art that various 
modi?cations and variations can be made in the present 
invention without departing from the scope or spirit of the 
invention. Other embodiments of the invention will be appar 
ent to those skilled in the art from consideration of the speci 
?cation and practice of the invention disclosed herein. It is 
intended that the Speci?cation and Examples be considered 
as exemplary only, and not intended to limit the scope and 
spirit of the invention. 
Unless otherwise indicated, all numbers expressing quan 
tities of ingredients, properties such as reaction conditions, 
and so forth used in the Speci?cation and Claims are to be 
understood as being modi?ed in all instances by the term 
“about.” Accordingly, unless indicated to the contrary, the 
numerical parameters set forth in the Speci?cation and 
Claims are approximations that may vary depending upon the 
desired properties sought to be determined by the present 
invention. 
Notwithstanding that the numerical ranges and parameters 
setting forth the broad scope of the invention are approxima 
tions, the numerical values set forth in the experimental or 
example sections are reported as precisely as possible. Any 
numerical value, however, inherently contain certain errors 
necessarily resulting from the standard deviation found in 
their respective testing measurements. 
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EXAMPLES 
Example 1 
Preparation of a Codeine-Racemic Norketamine 
Codrug 
Procedure for the Synthesis of Para-Nitrophenoxycarbamate 
of Norketamine. 
To a mixture of norketamine (0.05 g, 0.22 mmol) in anhy 
drous toluene (2 mL) and Na2CO3 (0.082 g) was added a 
solution of para-nitrophenyl chloroformate (0.129 g, 0.64 
mmol) in anhydrous toluene (2 mL). After heating for 8 hours 
at 85° C., the reaction mixture was cooled to room tempera 
ture and ?ltered. Toluene was evaporated under vacuum and 
the reaction mixture was diluted with dichloromethane 
(DCM). The DCM layer was washed 6 times with 50% aque 
ous NaHCO3 solution to remove the para-nitrophenol side 
product and then with brine. The DCM layer was then dried 
over anhydrous sodium sulfate, ?ltered, concentrated under 
vacuum to afford the para-nitrophenoxycarbamate of norket 
amine as apale solid. lH-NMR(CDC13): 6 8.17 (2H, dd), 7.87 
(1H, d), 7.37 (3H, m) 7.23 (2H, dd), 3.84 (1H, d), 2.55-1.71 
(8H). 
S cheme l a 
C1 
0 >:O 
NH2 OZNAQO 
—> 
NaZCO3, Anhyd. Toluene 
80° C. 
C1 
NOZ 
H 
O\H/N C1 
0 
0 
Procedure for the Synthesis Codeine-Racemic-Norketamine 
Codrug. 
In second step, the hybrid drug of codeine and racemic 
norketamine was synthesized in the following way. All glass 
ware was oven-dried and then cooled under a nitrogen atmo 
sphere. 51 mg (0.17 mmol) of codeine was placed in a round 
bottom ?ask under a nitrogen atmosphere and dissolved in 2 
mL of dry THF. The solution was cooled to 0° C. in an 
ice-bath. 8 mg (0.19 mmol) of NaH was added and the mix 
ture was allowed to stir for 5 minutes. 55 mg (0.14 mmol) of 
the para-nitrophenoxycarbamate of norketamine was dis 
solved in 4 mL of dry THF and the resulting solution was 
added dropwise to the reaction mixture; the reaction mixture 
was allowed to warm to room temperature. The progress of 
the reaction was monitored by TLC. After the reaction was 
complete, the reaction mixture was ?rst passed through a pad 
of celite and then concentrated under vacuum and then diluted 
with chloroform. The chloroform layer was washed 3 times 
with 50% aqueous NaHCO3 solution and once with brine. 
The chloroform layer was dried over anhydrous NaZSO4, 
?ltered, and then concentrated under vacuum to afford the 
US 8,710,070 B2 
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hybrid drug of codeine and racemic-norketamine as an amor 
phous solid. Column chromatography was used to get the 
diastereomeric mixture of the two codeine-norketamine 
codrugs. MS (ESI) m/Z 549 (M+H)+. 
S cheme l b 
1) NaH 
Anhyd. THF 
0° c. 
4> 
2) N02 
C1 
C1 N 
H 
Example 2 
Preparation of a Codeine-Racemic Ketamine Codrug 
Procedure for the Synthesis of Para-Nitrophenoxycarbamate 
of Ketamine. 
To a mixture of ketamine (0.052 g, 0.22 mmol) in anhy 
drous toluene (2 mL) and Na2CO3 (0.082 g) was added a 
solution of para-nitrophenyl chloroformate (0.129 g, 0.64 
mmol) in anhydrous toluene (2 mL). After heating for 8 hours 
at 100° C., the reaction mixture was cooled to room tempera 
ture and ?ltered. Toluene was evaporated under vacuum and 
the reaction mixture was diluted with dichloromethane 
(DCM). The DCM layer was washed 6 times with 50% aque 
ous NaHCO3 solution to remove the para-nitrophenol side 
product and then with brine. The DCM layer was then dried 
over anhydrous sodium sulfate, ?ltered, concentrated under 
vacuum to afford the para-nitrophenoxycarbamate of ket 
amine as a pale solid. MS (ESI) m/Z 403 (M+H)+. 
Scheme 13 
Cl 
0 \ >= NH O 
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-continued 
No2 
Procedure for the Synthesis Codeine-Racemic-Ketamine 
Codrug. 
In second step, the hybrid drug of codeine and racemic 
ketamine was synthesized in the following way. All glassware 
was oven-dried and then cooled under a nitrogen atmosphere. 
51 mg (0.17 mmol) of codeine was placed in a round-bottom 
?ask under a nitrogen atmosphere and dissolved in 2 mL of 
dry THF. The solution was cooled to 0° C. in an ice-bath. 8 mg 
(0.19 mmol) of NaH was added and the mixture was allowed 
to stir for 5 minutes. 56 mg (0.14 mmol) of the para-nitrophe 
noxycarbamate of ketamine was dissolved in 4 mL of dry 
THF and the resulting solution was added dropwise to the 
reaction mixture; the reaction mixture was allowed to warm 
to room temperature. The progress of the reaction was moni 
tored by TLC. After the reaction was complete, the reaction 
mixture was ?rst passed through a pad of celite and then 
concentrated under vacuum and then diluted with chloro 
form. The chloroform layer was washed 3 times with 50% 
aqueous NaHCO3 solution and once with brine. The chloro 
form layer was dried over anhydrous Na2SO4, ?ltered, and 
then concentrated under vacuum to afford the hybrid drug of 
codeine and racemic-ketamine as an amorphous solid. Col 
umn chromatography was used to get the diastereomeric mix 
ture of the two codeine-ketamine codrugs. MS (ESI) m/Z 563 
(M+H)+. 
S cheme l b 
1) NaH 
Anhyd. THF 
0° c. 
—> 
2) N02 
C1 N 
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Example 2 
Morphine+(+) Norketamine 
US 8,710,070 B2 
20 
Morphine & (+) Norketamine 
5 Male Rats #5-8 
Male Rats 5—8 
Day 2 Rats 5, 6 3 mgkg Mor & 3 mg/kg (+) Norketamine 
day 1 Rats 5’ 6 MOR 3 mgkg + SAL Day 2 Rats 7, 8 3 mgkg Mor & Saline 
day 1 Rats 7, 8 MOR 3 mgkg + (+) Norket 3mg/kg 
10 
1) Solution MOR 3 mg/ul (the same Mor. Sal. than has been TFLiImensity 40%, id1e activity 5%, cupoff 10 sec_ 
used today for Mor+(—) NK combination study, see p. 1) Solutions 
2) (+) Norketamine 3 mg/ml dose 3 mg/kg inj. 1 ml/kg _ 
(+) Norketamine 6 mg in 2 ml (3 mg/ml) 1) Morphmeisee P' 2 
(+) Norketamine HCl bottle #3 0.0069 2) (+) Norketamineisee p. 2 
Day 1 BWt. Day 2 BWt. 
20 
Rat 5 385 g 0.385 ml MOR + 0.385 ml SAL Rat 5 389 g 0.398 ml Mor & 0.389 ml (+) — NK 
Rat 6 392 g 0.392 ml MOR + 0.392 ml SA Rat 6 393 g 0.393 ml Mor & 0.393 ml (+) — NK 
Rat 7 400 g 0.40 ml MOR + 0.40 111 (+) NK Rat 7 398 g 0.398 ml Mor & 0.398 ml SAL 
Rat 8 455 g 0.455 ml MOR + 0.455 111 (+) NK Rat 8 458 g 0.458 ml Mor & 0.458 ml SAL 
25 
Inject 15 30 60 120 Inject 15 30 60 120 
Rat Baseline Baseline Time min. min. min. min. Rat Baseline Baseline Time min. min. min. min. 
30 
5 1.45 1.50 1:58 3.24 5.72 1.93 1.61 5 1.95 1.67 2:20 2.84 3.35 4.85 4.07 
6 1.36 1.24 1:59 3.55 6.2 4.50 5.44 6 1.44 1.49 2:21 5.20 6.17 5.32 3.35 
7 1.35 1.41 2:01 10.0 10.0 6.34 8.58 7 1.48 1.85 2:23 3.41 4.09 4.03 2.94 
8 1.38 1.40 2:02 10.0 10.0 10.0 5.43 8 2.63 2.42 2:24 3.48 3.22 3.01 2.12 
. . 35 Morph1ne & (—) Norketamine 
Male Rats 1—4 
Mal? Rats #14 40 Day 1 Rats 1, 2 3 mg/kg Morphine & Saline 
Day 2 Rats 1, 2 MOr 3 mg/kg & (_) Nork?tamin? 3 mg/kg Day 1 Rats 3, 4 3 mg/kg Morphine & 3 mgkg (—) Norketamine 
Day 2 Rats 3, 4 3 mgkg Mor & Saline 
_ _ _ _ _ TFLiIntensity 40%, idle activity 5%, cut-off 10 sec. 
TFLimtenslty 40%, 1dle act1V1ty 5%, cut-off 10 sec. . 
. Solutlons 
Solutlons 45 _ 
1) Morphineisee p_ 1 1) Morph1neisee p. 1 
2) (—) Norketamineisee p. 1 2) (—) Norketamineisee p. 1 
50 
Day 2 BWt. Day 1 BWt. 
Rat 1 398 g 0.398 ml Mor & 0.398 ml (—) NK Rat 1 424 g 0.424 ml Mor & 0.424 ml Saline 
Rat 2 423 g 0.423 ml Mor & 0.423 ml (—) NK Rat 2 407 g 0.407 ml Mor & 0.407 ml Saline 
Rat 3 425 g 0.425 ml Mor & 0.425 ml Saline Rat 3 433 g 0.433 ml Mor & 0.433 ml (—) NK 
Rat 4 377 g 0.377 ml Mor & 0.377 ml Saline 55 Rat 4 398 g 0.398 ml Mor & 0.398 ml (—) NK 
Inject 15 30 60 120 60 Inject 15 30 60 120 
Rat Baseline Baseline Time min. min. min. min. Rat Baseline Baseline Time min. min. min. min. 
1 1.63 1.52 1:10 1.83 2.27 2.53 2.37 1 1.60 1.52 1:45 2.92 3.64 3.28 2.74 
2 1.43 1.56 1:11 2.60 3.50 3.81 3.17 2 1.48 1.40 1:45 1.82 2.36 3.30 1.92 
3 1.70 1.68 1:13 2.03 2.74 1.94 1.48 3 1.42 1.36 1:46 2.37 2.28 1.99 1.37 
4 1.75 1.60 1:14 4.89 7.26 6.84 5.37 4 2.01 1.66 1:46 5.06 5.04 4.89 1.97 65 
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Morphine & (+) Norketamine 
US 8,710,070 B2 
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Morphine & (+) Norketamine 
M316 Rats 5.3 5 Male Rats 5—8 
Day 1 Rats 5, 6 3 mgkg Morphine & Saline gay i Eats 2’ g ; mgtg xorp?lne kg (+) Nork?tamm? 
Day 1 Rats 7, 8 3 mgkg Morphine & 3 mg/kg (+) Norketamine ay a S ’ mg g orp 1116 a 1m 
_ _ _ _ TFLiIntensity 40%, idle activity 5%, cut-off 10 seconds 
TFLiIntenSIty 40%, 1dle act1V1ty 5%, cut-off 10 sec. 10 Solutions: 
Solutions 1) Morphineisee p. 1 
1) Morphineisee p_ 1 2) (+) Norketamineisee p. 2 
2) (+) Norketamineisee p. 2 
15 
Day 2 BWt. 
Day 1 Bwt Rat 5 430 g 0.430 ml Mor & 0.430 ml (+) Norketamine 
Rat 6 415 g 0.415 ml Mor & 0.415 ml (+) Norketamine 
Rat 5 430 g 0.430 ml MOI & 0.430 ml Saline Rat 7 435 8 0-435 ml MOI & 0435 ml Saline 
Rat 6 414 g 0.414 ml MOI & 0.414 ml Saline 20 Rat 8 394 8 0-394 ml MOI & 0394 ml Saline 
Rat 7 431 g 0.431 ml Mor & 0.431ml(+)NK 
Rat 8 400 g 0.400 ml Mor & 0.400 ml (+) NK 
25 Inject 15 30 60 120 
Rat Baseline Baseline Time min. min. min. min. 
Inject 15 30 60 120 
Rat Baseline Baseline Time min min min min 5 1'55 1'63 10:35 3'54 4'92 6'20 2'96 
6 1044 1.38 2.97 5.70 10.0 7.62 
5 1_73 200 150 197 175 351 270 7 116 1.10 10:36 2.25 2.46 3.83 2.60 
6 1.45 1.39 1:50 2.88 3.86 3.69 2.17 30 8 1055 1-50 1.56 1.97 2.08 2.24 
7 1.18 1.10 1:51 10.0 10.0 10.0 5.39 
8 1.26 1.20 1:51 5.86 6.97 8.26 3.65 
What is claimed is: 
Morphlne & (-) Norketamme 35 1. A codrug of the following formula: 
Male Rats 1-4 Opioid —@ K?tamm?“ - Norketarmne 
Day 2 Rats 1, 2 3 mgkg Morphine & (—) Norketamine 40 
Day 2 Rats 3, 4 3 mgkg Morphine & Saline 
2. The codrug of claim 1, Wherein the linker is selected 
_ _ _ _ from the rou consistin of the followin formulas: 
TFLiIntenSIty 40%, 1dle act1V1ty 5%, cut-off 10 sec. g p g g 
Solutions 
45 R, 
1) Morphineisee p. 1 | 
2) (—) Norketamineisee p. 1 /O N\ 
R1 \H/ R2 
Y 
50 
Day 2 BWt. 
I Wherein Y is O or S; and Rl-O is an opioid moiety and 
Rat 1 427 g 0.427 ml Mor & 0.427 ml (—) Norketamme R2_NiR3 is a norketamine (R3:H) or ketamine 
Rat 2 410 g 0.410 ml Mor & 0.410 ml (—) Norketamme i . 
Rat 3 437 g 0.437 ml MOI & 0.437 ml Saline (R3mCH3) mOIety 
Rat 4 385 g 0.385 ml Mor & 0.385 ml Saline 55 
1|{3 
O X N 
R/ T T \RZ 
Inject 15 30 60 120 60 
Rat Baseline Baseline Time min min min min 0 O 
1 1.37 1.30 10:30 2.83 4.17 3.47 2.19 _ _ _ 
2 1.41 1.45 1.91 2.19 2.23 1.54 wherein X 1s nothing, 0, S, NH, NR4 (R4:a1ky1), (CH2), 
3 1-29 1-25 10131 1-49 1-50 2-55 1-31 (Where X:1-20, and the alkane moiety can be linear or 
4 1'68 1'53 2'85 3 '06 3 '43 1'78 65 branched), and Wherein R2-NiR3 is a norketamine 
moiety (R3IH) or a ketamine moiety (R3ICH3), and 
Rl-O is an opioid moiety. 
US 8,710,070 B2 
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3. The codrug of claim 1, wherein the opioid is selected 
from the group consisting of dihydroetorphine, butorphanol, 
pentazocine, morphine, phenazocine, hydromorphone, 
codeine, 3-acetylmorphine, oxymorphone, methadone, pro 
poxyphene, oxycodone, tramadol, hydrocodone, buprenor 
phine, levorphanol, dihydrocodeine, L-acetylmethadol, eth 
ylmorphine, nalbuphine, etorphine, buprenorphine, 
normethadone, dihydromorphine, noroxycodone, normor 
phine, norlevorphanol, and pharmaceutically acceptable 
salts, metabolites, enantiomers, diastereiomers and isomers 
thereof. 
4. The codrug of claim 2, Wherein the norketamine is 
selected from the group consisting of S-norketamine, R-nor 
ketamine, and racemic norketamine, and pharmaceutically 
acceptable salts and metabolites thereof; 
and Wherein the ketamine is selected from the group con 
sisting of S-ketamine, R-ketamine, and racemic ket 
amine, and pharmaceutically acceptable salts and 
metabolites thereof. 
5. The codrug of claim 1 having the formula la: 
la 
OR 
o 
N 
O H H \CH3 
0‘ 
NH X 0‘“ 
Cl T T 
o 0 
wherein X is a bond, CH2, (CH2)2, or (CH2)3; R is H or 
OCH3; and * represents racemic norketamine, S-norket 
amine, or R-norketamine; and analogs and stereoiso 
mers thereof. 
6. The codrug of claim 1 having the formula lb: 
1b 
OR 
o 
N 
O H H \CH3 
HN o“‘\\‘ 
Cl T 
Y 
WhereinY is O, S, or NR1; R is H or OCH3;R1 is alkyl; and 
* represents racemic norketamine, S-norketamine, or 
R-norketamine; and stereoisomers thereof. 
20 
25 
30 
40 
45 
50 
65 
24 
7. The codrug of claim 1 having the formula H: 
H 
OH 
O 
N 
H H \CH3 
\H/O\‘\‘\ 
and stereoisomers thereof. 
8. The codrug of claim 1 having the formula III: 
III 
OH 
H CH3 
Cl 
and stereoisomers thereof. 
9. A codeine-racemic norketamine codrug having the for 
mula: 
Cl 
10. A codeine-racemic ketamine codrug comprising the 
formula: 
Cl 
11. The codrug of claim 1, Wherein the opioid moiety is 
morphine, and the ketamine moiety is S-ketamine, and 
Wherein the linker is a carbamate. 
US 8,710,070 B2 
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12. The codrug of claim 1, wherein the opioid moiety is 
3-acetylmorphine, and the ketamine moiety is S-ketamine, 
and Wherein the linker is a carbamate. 
13. The codrug of claim 1, Wherein the opioid moiety is 
codeine, and the ketamine moiety is S-ketamine, and Wherein 
the linker is a carbamate. 
14. The codrug of claim 1, Wherein the opioid moiety is 
oxycodone and the ketamine moiety is S-ketamine, and 
Wherein the linker is a carbamate. 
15. The codrug of claim 1, Wherein the opioid moiety is 
oxymorphone, and the ketamine moiety is S-ketamine, and 
Wherein the linker is a carbamate. 
16. The codrug of claim 1, Wherein the opioid moiety is 
hydromorphone, and the ketamine moiety is S-ketamine, and 
Wherein the linker is a carbamate. 
17. The codrug of claim 1, Wherein the opioid moiety is 
butorphanol, and the ketamine moiety is S-ketamine, and 
Wherein the linker is a carbamate. 
18. The codrug of claim 1, Wherein the opioid moiety is 
bupernorphine, and the ketamine moiety is S-ketamine, and 
Wherein the linker is a carbamate. 
19. The codrug of claim 1, Wherein the opioid moiety is 
tramadol, and the ketamine moiety is S-ketamine, and 
Wherein the linker is a carbamate. 
20. The codrug of claim 1, Wherein the opioid moiety is 
levorphanol, and the ketamine moiety is S-ketamine, and 
Wherein the linker is a carbamate. 
21. The codrug of claim 1, Wherein the opioid moiety is 
morphine, and the norketamine moiety is S-norketamine, and 
Wherein the linker is a carbamate. 
22. The codrug of claim 1, Wherein the opioid moiety is 
3-acetylmorphine, and the norketamine moiety is S-norket 
amine, and Wherein the linker is a carbamate. 
23. The codrug of claim 1, Wherein the opioid moiety is 
codeine, and the norketamine moiety is S-norketamine, and 
Wherein the linker is a carbamate. 
24. The codrug of claim 1, Wherein the opioid moiety is 
oxycodone, and the norketamine moiety is S-norketamine, 
and Wherein the linker is a carbamate. 
25. The codrug of claim 1, Wherein the opioid moiety is 
oxymorphone, and the norketamine moiety is S-norketamine, 
and Wherein the linker is a carbamate. 
26. The codrug of claim 1, Wherein the opioid moiety is 
hydromorphone, and the norketamine moiety is S-norket 
amine, and Wherein the linker is a carbamate. 
27. The codrug of claim 1, Wherein the opioid moiety is 
butorphanol, and the norketamine moiety is S-norketamine, 
and Wherein the linker is a carbamate. 
28. The codrug of claim 1, Wherein the opioid moiety is 
bupernorphine, and the norketamine moiety is S-norket 
amine, and Wherein the linker is a carbamate. 
29. The codrug of claim 1, Wherein the opioid moiety is 
tramadol, and the norketamine moiety is S-norketamine, and 
Wherein the linker is a carbamate. 
30. The codrug of claim 1, Wherein the opioid moiety is 
levorphanol, and the norketamine moiety is S-norketamine, 
and Wherein the linker is a carbamate. 
31. A pharmaceutical composition comprising an analge 
sically effective amount of a compound selected from the 
group consisting of: 
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the compound of formula la: 
la 
OR 
o 
N 
O H H \CH3 
NH X 0““ 
Cl T T 
o 0 
wherein X is a bond, CH2, (CH2)2, or (CH2)3; R is H or 
OCH3; and * represents racemic norketamine, S-norket 
amine, or R-norketamine; 
the compound of the formula lb: 
1b 
OR 
o 
N 
O H H \CH3 
\“ 
HN 0‘“ 
Cl T 
Y 
WhereinY is O, S, or NR1 ; R is H or OCH3; R1 is alkyl, and 
represents racemic norketamine, S-norketamine, or 
R-norketamine; 
the compound of the formula H: 
H 
OH 
O 
N 
O H H \CH3 
"III’HN O\\“‘\ 
Cl 11/ 
O 
and the compound of the formula 111: 
Ill 
OH 
O 
N 
H H \CH3 
and at least one pharmaceutically acceptable excipient. 


